dimarts, 23 de febrer del 2016

MassDevice.com +3 | The top 3 medtech stories for February 23, 2016

plus3-1x1

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. TransMedics launches pivotal trial for OCS liver transplant system

MassDevice.com news

TransMedics said that it launched a pivotal study of its OCS Liver device, which is designed to keep donated human liver warm and perfused until transplantation.

Andover, Mass.-based TransMedics said the 1st liver transplantation using OCS Liver was performed at Mass. General Hospital by Dr. James Markmann, a lead investigator for the 300-patient OCS Liver Protect trial and chairman of its steering committee. Read more


2. FDA approves Boston Scientific’s Acuity X4 quad leads

MassDevice.com news

Boston Scientific said that it won pre-market approval from the FDA for its Acuity X4 quadripolar leads for its cardiac resynchronization devices.

The approval marks the 1st time the Marlborough, Mass.-based company has a full quadripolar CRT system on the U.S. market. The Acuity X4 leads are designed to work with Boston’s Dynagen X4 and Inogen X4 CRT-Ds. Read more


1. Medtronic claims title to world’s 1st app-based remote monitoring for pacemakers

MassDevice.com news

Medtronic said that its Canadian subsidiary won approval there for the world’s 1st app-based remote monitor for pacemakers, the MyCareLink Smart system.

The Health Canada nod allows patients with compatible Medtronic pacers to use a smartphone or tablet to send data to caregivers, using a handheld portable device reader and the MyCareLink Smart app, the Fridley, Minn.-based medical device company said. Read more

The post MassDevice.com +3 | The top 3 medtech stories for February 23, 2016 appeared first on MassDevice.



from MassDevice http://ift.tt/1PWFwSm

Cap comentari:

Publica un comentari a l'entrada